Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, U.S.A.
Cancer Genomics Proteomics. 2012 Sep-Oct;9(5):297-310.
Breast cancer (BC) remains the most common cancer type diagnosed in women. Although targeted therapies have improved patient survival for advanced BC, these tumors frequently relapse due to drug resistance mechanisms. A systems biology approach integrates DNA, RNA and protein alterations generated from multidimensional platforms to better understand the mechanisms that regulate the metastatic process. Downstream functional analyses in pre-clinical studies might integrate the role of these aberrations into the cell, leading to discovery of new therapeutic targets. In the present report, we review relevant findings associated with genomic, transcriptomic and proteomic analyses and the contribution of the systems biology concept to the interpretation of these data in the metastatic context. Also, we highlight the importance of re-designing clinical trials towards metastasis prevention for improvement of personalized care.
乳腺癌（BC）仍然是女性中最常见的诊断癌症类型。尽管靶向治疗已经提高了晚期 BC 患者的生存率，但这些肿瘤由于耐药机制经常复发。系统生物学方法整合了来自多维平台的 DNA、RNA 和蛋白质改变，以更好地理解调节转移过程的机制。临床前研究中的下游功能分析可能将这些异常的作用整合到细胞中，从而发现新的治疗靶点。在本报告中，我们回顾了与基因组、转录组和蛋白质组分析相关的相关发现，以及系统生物学概念对转移背景下这些数据解释的贡献。此外，我们强调了重新设计临床试验以预防转移以改善个性化护理的重要性。
